Theradiag

Theradiag EBIT per Share

The EBIT per Share of Theradiag (ALTER.PA) as of Oct 23, 2026 is -0.03 EUR. In the previous year, EBIT per Share was -0.07 EUR — a change of -58.02% (higher).

EBIT per Share

-0.03EUR

YoY

-58.02%

Last updated:

EBIT per Share of Theradiag is 2022 -0.03 EUR. EBIT per Share of Theradiag was 2021 -0.07 EUR. It decreases by -58.02% higher compared to the previous year.

The Theradiag EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
-0.08 EUR
Jan 1, 2019
-0.07 EUR
Jan 1, 2020
-0.06 EUR
Jan 1, 2021
-0.07 EUR
Jan 1, 2022
-0.03 EUR
Jan 1, 2023 (e)
0.03 EUR
Jan 1, 2024 (e)
0.15 EUR
Jan 1, 2025 (e)
0.01 EUR
The Theradiag EBIT per Share history
YEAREBIT per ShareYoY
est0.01EUR-90.20%
est0.15EUR+382.52%
est0.03EUR-212.57%
-0.03EUR-58.02%
-0.07EUR+6.56%
-0.06EUR-4.53%
-0.07EUR-13.34%
-0.08EUR-82.17%
-0.43EUR+43.49%
-0.30EUR-47.91%
-0.57EUR-9.96%
-0.63EUR-4.97%
-0.67EUR+155.78%
-0.26EUR+66.10%
-0.16EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Theradiag Stock analysis

What does Theradiag do? Theradiag SA is a French company specialized in the development, production, and marketing of diagnostics for personalized medicine. The company was founded in 1986 and is headquartered in Marne-la-Vallée, France. It is listed on the stock exchange and belongs to the Euronext Growth market segment. Theradiag offers diagnostics for autoimmune, infectious, cancer, and inflammatory diseases. Its business model involves developing innovative diagnostics and selling them to clinical laboratories and hospitals. The company has a network of distributors to sell its products globally. Its offerings include diagnostics for autoimmune diseases, infections, cancer, and inflammation, as well as personalized medicine. The company invests in research and development to improve patients' health and well-being. Theradiag is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Theradiag stock

EBIT per Share of Theradiag is -0.03 EUR in 2022.

EBIT per Share of Theradiag changed from -0.07 EUR to -0.03 EUR, representing a -58.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Theradiag since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Theradiag

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Theradiag